Bispecific Antibody Production Protocol and FAQs

Bispecific antibody (BsAb), usually composed of two different antigen-binding fragments, is an antibody molecule that can simultaneously recognize two different antigens or different epitopes of the same antigen. Such a design allows BsAb to bridge cell-cell interactions, such as binding to both tumor cells and immune effector cells, thereby increasing the efficiency of immune killing. The structure of BsAb is diverse, including bispecific IgG, antibody-antibody hybrids, fragment antibody fusions (such as bivalent mice or single-chain antibody fragments), etc. Compared with monospecific antibodies, bispecific antibodies have shown significant advantages in the fields of tumor immunotherapy, autoimmune diseases and infectious diseases.

Principle of Bispecific Antibody Production

The design concept of bispecific antibodies is based on optimizing the functional characteristics of antibodies, achieving better therapeutic effects by realizing the following functions:

Cross Linked Target Cells

Bispecific antibody simultaneously bind target cells and effector cells, bringing them closer together to enhance immune response.

Direct Inhibition of Signaling Pathways

Blocking two signaling pathways provides stronger therapeutic inhibition effects.

Double Antigen Recognition

By simultaneously recognizing two different antigens, it increases specificity and reduces side effects.

Select two different binding sites for the target antigen and design corresponding heavy and light chains. Then, these genes are introduced into host cells through cell expression systems (such as CHO cells) to achieve antibody expression and assembly. After removing impurities through purification processes, functional bispecific antibodies with two specific binding abilities are obtained. This technology is widely used in targeted therapy for various diseases such as cancer.

The Steps of Bispecific Antibody Production

Design and Cloning

Determine the sequence information of the two antigens that need to be bound. An antibody gene capable of expressing two different antigen-binding fragments is designed, and the variable regions of two different antibodies can be selected. Create a gene construct that fuses these two variable region sequences, and select the appropriate linker peptide to ensure correct folding.

Vector Construction

The designed gene was inserted into the expression vector. For complex antibody structures, multiple vectors and different promoters may be required. If you plan to use mammalian cells such as CHO cells for expression, you may need to use specific eukaryotic expression vectors.

Expression System Selection

According to the complexity of the antibody, the appropriate host cells were selected, such as E.coli for bispecific antibodies with simple structure, CHO or HEK293 cells for complex structures. Transfect the cells and optimize the conditions to improve the expression efficiency.

Isolation and Purification

Purification of bispecific antibodies by affinity chromatography, due to its complex structure, may require the combination of a variety of chromatographic techniques such as protein A / G affinity chromatography, ion exchange and size exclusion chromatography. The purification effect was evaluated by SDS-PAGE and high performance liquid chromatography (HPLC).

Functional Detection

In vitro binding assays, such as ELISA or surface plasmon resonance (SPR), were performed to detect the binding activity of bispecific antibodies. Evaluate its biological functions, such as cytotoxicity analysis, and detect its ability to guide effector cells to inhibit target cells.

Stability and Storage

The storage stability of the bispecific antibody was tested to determine the appropriate buffer and storage conditions. The effect of different temperature and time on antibody activity was investigated by long-term stability test.

Figure 1. Schematic representations of bispecific antibody (bsAb) formats discussed in this article. (a) Single chain Fv (scFv), (b) tandem scFv format of bispecific T cell engager (BiTE), (c) disulfide-linked diabody format of dual affinity retargeting (DART) bsAb, (d) tandam diabody (TandAb), (e) conventional immunoglobulin G (IgG), (f) IgGs with additional binding units such as scFv, (g) dual variable domain immunoglobulin (DVD-Ig), (h) quadromab bsAb, (i) knobs-into-holes (KiH) bsAb with a common light chain, (j) KiH-CrossMabCH1-CL, and (k) bsAb by controlled Fab arm exchange(cFAE).

Advantages of Bispecific Antibody

Specific Enhancement

By simultaneously recognizing two different antigens or epitopes, bispecific antibodies can improve targeting accuracy, reduce the impact on non target cells, and thus reduce the side effects of treatment.

Dual Function

Bispecific antibodies can combine two functions in the same molecule. For example, they can simultaneously block signaling pathways and recruit immune cells to destroy target cells. This multifunctionality makes its treatment particularly effective in complex pathological environments.

Bridge Effect

Bispecific antibodies can directly guide immune effector cells (such as T cells or natural killer cells) to tumor cells or infectious pathogens, thereby enhancing the clearance efficiency of the immune system. For example, through T cell redirection technology, bsAb can activate the patient's own immune response to attack cancer cells.

Reducing Drug Tolerance

Due to the ability of bispecific antibodies to target multiple targets simultaneously, this reduces the possibility of developing drug tolerance to a single target, making treatments for cancer and infectious diseases more durable and effective.

application of Bispecific Antibody

Immune Disorders

In some autoimmune diseases, bispecific antibodies can be designed to suppress overactive immune responses or provide precise immune regulation when needed. This brings new hope for disease management and treatment.

Infectious Disease Treatment

For viral and bacterial infections, bispecific antibodies can simultaneously block the invasion pathway of the virus and mobilize immune cells to suppress the infection, making it a powerful tool for treating stubborn infections.

Biomarker Detection

Bispecific antibodies are also used to develop more sensitive and specific diagnostic tools that can simultaneously detect multiple biomarkers in samples, improving diagnostic accuracy and efficiency.

Regenerative Medicine and Tissue Engineering

In regenerative medicine, bispecific antibodies can be used to regulate specific cellular signaling pathways, promote tissue regeneration and repair, and provide innovative therapeutic methods.

Alpha Lifetech provides research and development of Bispecific Antibodies, and has successfully achieved efficient and stable production of bispecific antibodies through the use of advanced protein engineering technology and cell culture processes.

FAQ

1. The structure of bispecific antibodies is complex, and different construction forms have differences in stability, expression and functionality.

Solution : Develop a variety of bispecific antibody formats, such as bivalent bispecific, tetravalent tetraspecific, etc., and select the best design according to application requirements. Computer-aided design (CAD) was used to optimize the interaction interface of antibodies to improve the stability and functionality of the molecules.
2. The bispecific antibody may have low expression efficiency and low yield due to its complex structure.

Solution : Highly efficient expression systems, such as CHO cell lines, were selected and the host cells were optimized by genetic engineering techniques. Adjusting culture conditions and expression vectors, including using strong promoters and optimizing mRNA sequences, to increase expression levels.
3. Due to the complex structure of bispecific antibodies, traditional antibody purification methods may not be applicable, and new purification strategies need to be developed.

Solution : Affinity chromatography combined with anion and cation exchange chromatography was used to separate and purify the target molecules more effectively. Develop specific purification tags or binding motifs to facilitate the extraction of target antibodies in complex mixtures.
4. Bispecific antibody molecules may aggregate during storage and transportation, affecting their stability and function.

Solution : Physical and chemical studies were carried out to optimize the buffer system and storage conditions to maintain protein stability. Screening and optimization of antibody fragments and linker peptides at the design stage to reduce aggregation tendencies.
5. Bispecific antibodies may trigger an immune response, thereby reducing efficacy and safety.

Solution : The immunogenicity is reduced by antibody humanization technology. Potential T cell and B cell epitopes were predicted and excluded by bioinformatics tools.
6. The functional activity of bispecific antibodies may be disturbed, especially when there is a negative interaction between different antigen binding domains.

Solution : Optimize the spatial configuration between antibodies and enhance their binding ability to different targets. In vitro functional assays and cell function experiments were used to verify and optimize the biological activity of the bispecific antibody.

reference

[1] de Assis LH, Fassi DE, Hutchings M. Bispecific antibody therapies. Hematology Am Soc Hematol Educ Program. 2023;2023(1):216-222. doi:10.1182/hematology.2023000508

[2] Thakur A, Huang M, Lum LG. Bispecific antibody based therapeutics: Strengths and challenges. Blood Rev. 2018;32(4):339-347. doi:10.1016/j.blre.2018.02.004

[3] Minson A, Dickinson M. Glofitamab CD20-TCB bispecific antibody. Leuk Lymphoma. 2021;62(13):3098-3108. doi:10.1080/10428194.2021.1953016

[4] Shim H. Bispecific Antibodies and Antibody-Drug Conjugates for Cancer Therapy: Technological Considerations. Biomolecules. 2020;10(3):360. Published 2020 Feb 26. doi:10.3390/biom10030360

[5] Karbyshev MS, Kalashnikova IV, Dubrovskaya VV, Baskakova KO, Kuzmichev PK, Sandig V. Trends and challenges in bispecific antibody production. J Chromatogr A. 2025;1744:465722. doi:10.1016/j.chroma.2025.465722